<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><description>米内网是中国领先的集医药健康产业研究、医院市场研究、零售市场研究、商业渠道研究、互联网在线医药健康信息服务于一体的综合性专业信息服务平台。目前拥有七项数据分析技术获国家专利，每月收集数据3000多万条，有63个专业数据库为医药健康行业服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 22 Mar 2021 17:26:33 +0800</pubDate><image><url>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</url><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>7款抗ED国产1类新药来袭，扬子江冲刺首个！四川药企将拿下首仿，30个新品在路上</title><link>https://mp.weixin.qq.com/s/Efihe_67x0iQ56UsXBWteg</link><description></description><content:encoded><![CDATA[7款抗ED国产1类新药来袭，扬子江冲刺首个！四川药企将拿下首仿，30个新品在路上]]></content:encoded><pubDate>Mon, 22 Mar 2021 16:10:35 +0800</pubDate></item><item><title>【重磅】齐鲁两款1类新药来势汹汹，剑指1000亿市场</title><link>https://mp.weixin.qq.com/s/UIZK_mbIiPe12f5zuZHSew</link><description></description><content:encoded><![CDATA[【重磅】齐鲁两款1类新药来势汹汹，剑指1000亿市场]]></content:encoded><pubDate>Mon, 22 Mar 2021 16:10:35 +0800</pubDate></item><item><title>【瞩目】成都倍特将拿下$15亿抗血栓药，这款注射剂首家过评</title><link>https://mp.weixin.qq.com/s/dlmXPrLPknGin09dRjp41A</link><description></description><content:encoded><![CDATA[【瞩目】成都倍特将拿下$15亿抗血栓药，这款注射剂首家过评]]></content:encoded><pubDate>Mon, 22 Mar 2021 16:10:35 +0800</pubDate></item><item><title>【关注】7亿免疫抑制剂首仿，这家企业将获批</title><link>https://mp.weixin.qq.com/s/MIHMnMBhoLwYlKyA71JxTg</link><description></description><content:encoded><![CDATA[【关注】7亿免疫抑制剂首仿，这家企业将获批]]></content:encoded><pubDate>Mon, 22 Mar 2021 16:10:35 +0800</pubDate></item><item><title>创新药累计大卖破80亿！这家创新药企17款1类新药抢眼，净利预增155%-185%</title><link>https://mp.weixin.qq.com/s/mICO_8NU80ll-nTvmTactQ</link><description></description><content:encoded><![CDATA[创新药累计大卖破80亿！这家创新药企17款1类新药抢眼，净利预增155%-185%]]></content:encoded><pubDate>Sun, 21 Mar 2021 07:47:58 +0800</pubDate></item><item><title>4个注射剂被调查！齐鲁、礼来……主动降价，近6000家药企被点名，中标、挂网产品或撤网</title><link>https://mp.weixin.qq.com/s/KS5AILHR7JpEq2rjeRSVow</link><description></description><content:encoded><![CDATA[4个注射剂被调查！齐鲁、礼来……主动降价，近6000家药企被点名，中标、挂网产品或撤网]]></content:encoded><pubDate>Sat, 20 Mar 2021 07:57:37 +0800</pubDate></item><item><title>56个药品被点名！正大天晴已突围，恒瑞、奥赛康要冲刺，赛诺菲重磅新药被哄抢</title><link>https://mp.weixin.qq.com/s/_ZjcF9DQaW16lzZj7eYAeA</link><description></description><content:encoded><![CDATA[56个药品被点名！正大天晴已突围，恒瑞、奥赛康要冲刺，赛诺菲重磅新药被哄抢]]></content:encoded><pubDate>Fri, 19 Mar 2021 16:17:44 +0800</pubDate></item><item><title>【重磅】汇宇再发威，入局10亿注射剂！三家四川药企争首仿</title><link>https://mp.weixin.qq.com/s/nZaRtPGg6NuXdJov1n2HfQ</link><description></description><content:encoded><![CDATA[【重磅】汇宇再发威，入局10亿注射剂！三家四川药企争首仿]]></content:encoded><pubDate>Fri, 19 Mar 2021 16:17:44 +0800</pubDate></item><item><title>【瞩目】复星冲击首仿，瞄准灵北和大冢的$10亿精神病药</title><link>https://mp.weixin.qq.com/s/qS2R5AxMmtat4QYQpp_00A</link><description></description><content:encoded><![CDATA[【瞩目】复星冲击首仿，瞄准灵北和大冢的$10亿精神病药]]></content:encoded><pubDate>Fri, 19 Mar 2021 16:17:44 +0800</pubDate></item><item><title>【焦点】8亿口服抗生素，科伦、京新即将获批</title><link>https://mp.weixin.qq.com/s/Ra5k1g4vWuQZxzKlPtt8Kg</link><description></description><content:encoded><![CDATA[【焦点】8亿口服抗生素，科伦、京新即将获批]]></content:encoded><pubDate>Fri, 19 Mar 2021 16:17:44 +0800</pubDate></item><item><title>药企9亿收购“爆雷”，虚增1.7亿利润被罚！誉衡、瑞康……23家扭亏，9家首亏后“翻盘”</title><link>https://mp.weixin.qq.com/s/B_5uTmvltYYHAMy6jDpe9g</link><description></description><content:encoded><![CDATA[药企9亿收购“爆雷”，虚增1.7亿利润被罚！誉衡、瑞康……23家扭亏，9家首亏后“翻盘”]]></content:encoded><pubDate>Thu, 18 Mar 2021 17:00:23 +0800</pubDate></item><item><title>【获批】齐鲁拿下5亿口服降糖药！阿斯利康9成市场再受冲击</title><link>https://mp.weixin.qq.com/s/9yehd7K7HI8XlNoKpLGdLg</link><description></description><content:encoded><![CDATA[【获批】齐鲁拿下5亿口服降糖药！阿斯利康9成市场再受冲击]]></content:encoded><pubDate>Thu, 18 Mar 2021 17:00:23 +0800</pubDate></item><item><title>【点赞】悦康药业：以创新与国际化打造银杏叶提取物注射液制剂标杆</title><link>https://mp.weixin.qq.com/s/faUE7Bu3DiAvbTzlQWgmpw</link><description></description><content:encoded><![CDATA[【点赞】悦康药业：以创新与国际化打造银杏叶提取物注射液制剂标杆]]></content:encoded><pubDate>Thu, 18 Mar 2021 17:00:23 +0800</pubDate></item><item><title>【关注】7亿抗肿瘤注射剂！奥赛康首家过评</title><link>https://mp.weixin.qq.com/s/OgNO4ZBAXHRdoNPbJ0r24Q</link><description></description><content:encoded><![CDATA[【关注】7亿抗肿瘤注射剂！奥赛康首家过评]]></content:encoded><pubDate>Thu, 18 Mar 2021 17:00:23 +0800</pubDate></item><item><title>石药大丰收！49个创新药亮眼，43个过评品种霸屏，抗肿瘤药、心血管药销售大涨</title><link>https://mp.weixin.qq.com/s/vZDNuNkJoMrEIqiJ5rcgUA</link><description></description><content:encoded><![CDATA[石药大丰收！49个创新药亮眼，43个过评品种霸屏，抗肿瘤药、心血管药销售大涨]]></content:encoded><pubDate>Wed, 17 Mar 2021 16:06:06 +0800</pubDate></item><item><title>【瞩目】70亿祛痰品种新剂型！这家广州药企拿下</title><link>https://mp.weixin.qq.com/s/WmUmal5mKVQHb4ngCRapbA</link><description></description><content:encoded><![CDATA[【瞩目】70亿祛痰品种新剂型！这家广州药企拿下]]></content:encoded><pubDate>Wed, 17 Mar 2021 16:06:06 +0800</pubDate></item><item><title>【关注】世界睡眠日，良好免疫源于优质睡眠</title><link>https://mp.weixin.qq.com/s/RExEJpoqmonVrPjvCLMaVw</link><description></description><content:encoded><![CDATA[【关注】世界睡眠日，良好免疫源于优质睡眠]]></content:encoded><pubDate>Wed, 17 Mar 2021 16:06:06 +0800</pubDate></item><item><title>【市场】6亿抗过敏药，药企两大独家剂型过评</title><link>https://mp.weixin.qq.com/s/qqG5N3IM56XfkOMsmgyqPg</link><description></description><content:encoded><![CDATA[【市场】6亿抗过敏药，药企两大独家剂型过评]]></content:encoded><pubDate>Wed, 17 Mar 2021 16:06:06 +0800</pubDate></item><item><title>第五批集采盯上1000亿市场？扬子江、齐鲁、科伦......79个药品已备好！这些胰岛素或专项集采</title><link>https://mp.weixin.qq.com/s/48j-_y97GB5JOTS8s4Fqtw</link><description></description><content:encoded><![CDATA[第五批集采盯上1000亿市场？扬子江、齐鲁、科伦......79个药品已备好！这些胰岛素或专项集采]]></content:encoded><pubDate>Tue, 16 Mar 2021 16:10:34 +0800</pubDate></item><item><title>【重磅】汇宇将拿下18亿抗肿瘤大品种</title><link>https://mp.weixin.qq.com/s/e0KUtqqktUIih0bdknoq4w</link><description></description><content:encoded><![CDATA[【重磅】汇宇将拿下18亿抗肿瘤大品种]]></content:encoded><pubDate>Tue, 16 Mar 2021 16:10:34 +0800</pubDate></item></channel></rss>